180 Life Sciences 

180 Life Sciences Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company was founded by Marc Feldmann, Lawrence J. Steinman, and Jonathan B. Rothbard on September 7, 2016 and is headquartered in Palo Alto, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q4 2023

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PALO ALTO, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced the formation of a scientific advisory board (SAB).

180 Life Sciences Corp. Forms Scientific Advisory Board

The stock price of 180 Life Sciences Corp (NASDAQ: ATNF) increased by over 11% pre-market today. This is why it happened.

180 Life Sciences (ATNF) Stock: Why The Price Jumped Up Today

PALO ALTO, Calif., Dec. 28, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that the Company will participate in the Biotech Showcase 2022 Virtual Conference to be held January 10-12, 2022.

180 Life Sciences Corp. To Participate in the Biotech Showcase 2022 Virtual Conference To be Held January 10-12, 2022

PALO ALTO, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it has entered into a new, exclusive global licensing agreement with The University of Oxford (“Oxford”) for the development and commercialization of HMGB1, a regenerative molecule for promoting liver repair and regeneration. Under the terms of the transaction, the Company will pay Oxford a small one-time upfront license fee, which will have an insignificant impact on the 2022 expenditure rate; and any further payments are contingent upon the achievement of certain clinical, regulatory and sales milestones.

180 Life Sciences Corp. Enters into a License Agreement with University of Oxford for Regenerative Molecule HMGB1 for Liver Diseases

First Wave BioPharma

Petros Pharmaceuticals

Xeris Biopharma Holdings

You can buy these penny stocks for under $5 but are they worth the risk? The post 4 Penny Stocks To Buy For Under $5 Before 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Penny Stocks To Buy For Under $5 Before 2022

PALO ALTO, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today provided follow-up information on the top line results of Oxford University and the Company's Phase 2b clinical trial for Dupuytren's disease announced on December 1, 2021.

180 Life Sciences Provides Follow-Up Information on Oxford University and the Company's Successful Dupuytren's Phase 2b Clinical Trial Results

‘Cellular and Molecular Profiling of Dupuytren's Disease: From the Lab to the Clinic' Presented Wednesday, December 1, 2021, at 3pm EST ‘Cellular and Molecular Profiling of Dupuytren's Disease: From the Lab to the Clinic' Presented Wednesday, December 1, 2021, at 3pm EST

180 Life Sciences Corp. Co-Founder Prof. Jagdeep Nanchahal Presents Keynote Address at the 2021 International Dupuytren Symposium, Including Top Line Data From the Phase 2b Clinical Trial

New IP Relates to a Method for Treating Chronic Pain or Associated Conditions/Symptoms with Novel Compositions Including Certain Phenyl Substituted Cyclohexenyl Compounds Related to Cannabidiol (CBD) New IP Relates to a Method for Treating Chronic Pain or Associated Conditions/Symptoms with Novel Compositions Including Certain Phenyl Substituted Cyclohexenyl Compounds Related to Cannabidiol (CBD)

180 Life Sciences Corp. Expands Patent Portfolio

The stock price of 180 Life Sciences Corp (NASDAQ: ATNF) increased by over 7% during intraday trading today. This is why it happened.

180 Life Sciences (ATNF) Stock: Why The Price Jumped Today

‘Re-purposing anti-TNF for Dupuytren's Disease' Being Presented Wednesday, December 1, 2021, at 3pm EST ‘Re-purposing anti-TNF for Dupuytren's Disease' Being Presented Wednesday, December 1, 2021, at 3pm EST

180 Life Sciences Corp. Co-Founder Prof. Jagdeep Nanchahal to Present a Keynote Address at the 2021 International Dupuytren Symposium

Highly Accomplished Strategy, Corporate/Business Development, Finance and Operations Executive With 20 Years of Biopharma Experience Highly Accomplished Strategy, Corporate/Business Development, Finance and Operations Executive With 20 Years of Biopharma Experience

180 Life Sciences Corp. Names Quan A. Vu Chief Operating Officer/Chief Business Officer

PALO ALTO, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that its pre-clinical study report on the effects of CBG (cannabigerol) derivatives on pain, inflammation and obesity was published in the journal Molecules.

180 Life Sciences Corp. Publishes Pre-Clinical Study Report on the Effects of CBG Derivatives on Pain, Inflammation and Obesity in The Journal Molecules

180 Life Sciences Corp. (NASDAQ:ATNF) shares are trading higher Monday, although there looks to be no company-evident news to explain the jump in price. The stock was trending on social media sites throughout the day such as StockTwits.

180 Life Sciences Stock Bounces Off Support: What's Next?

Notice of Allowance Issued for “Method for Reducing Post-Operative Cognitive Dysfunction (POCD)” Notice of Allowance Issued for “Method for Reducing Post-Operative Cognitive Dysfunction (POCD)”

180 Life Sciences Corp. Continues To Expand Intellectual Property Portfolio

Three Anti-TNF Product Candidates To Be Included in Expected Global Agreement Three Anti-TNF Product Candidates To Be Included in Expected Global Agreement

Celltrion Healthcare and 180 Life Sciences Enter Into Memorandum of Understanding for a Supply Agreement for the Ongoing Supply of Drug for Anti-TNF Product Trials for Novel Indications

180 Life Sciences' Prof. Sir Marc Feldmann, who co-founded ATNF with cannabis trailblazer Prof. Raphael Mechoulam, joins the podcast with Dr. Jonathan Rothbard, Chief Science Officer.

180 Life Sciences: Looking At Inflammation With Cannabis (Podcast Transcript)

180 Life Sciences' Prof. Sir Marc Feldmann, who co-founded ATNF with cannabis trailblazer Prof. Raphael Mechoulam, joins the podcast with Dr. Jonathan Rothbard, Chief Science Officer. Focusing on pain and inflammation space. Aiming for FDA approval. Human clinical trials.

180 Life Sciences: Looking At Inflammation With Cannabis (Podcast)

PALO ALTO, Calif., Aug. 30, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, the "Company"), a clinical-stage biotechnology company with its lead indication in Phase 2b clinical trial, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today released the following letter to stockholders from its Chief Executive Officer, Dr. James Woody.

180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Stockholders

PALO ALTO, Calif., Aug. 24, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the "Company"), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced the closing of its previously announced private placement of 2,500,000 shares of its common stock and accompanying warrants to purchase an aggregate of up to 2,500,000 shares of common stock at a combined purchase price of $6.00 per share and accompanying warrant. The warrants are exercisable immediately at an exercise price of $7.50 per share and will expire five years from the date of issuance. Gross proceeds were approximately $15.0 million, before deducting placement agent fees and other offering expenses. The Company currently intends to use the net proceeds from this offering for general corporate purposes, working capital, and for the research and development of the Company's programs that are not funded by grants.

180 Life Sciences Corp. Announces Closing of $15.0 Million Private Placement

Another capital raise less than a year after the company's stock market debut is more than a little troubling.

Why 180 Life Sciences Stock Is Falling Today

PALO ALTO, Calif., Aug. 19, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it has entered into securities purchase agreements with certain institutional investors to raise approximately $15.0 million through the private placement of 2,500,000 shares of its common stock and accompanying warrants to purchase an aggregate of up to 2,500,000 shares of common stock at a combined purchase price of $6.00 per share and accompanying warrant.  The warrants will be exercisable immediately at an exercise price of $7.50 per share and will expire five years from the date of issuance. The closing of the private placement is expected to occur on August 23, 2021, subject to the satisfaction of certain customary closing conditions set forth in the securities purchase agreements.

180 Life Sciences Corp. Announces $15.0 Million Private Placement

Collaboration Between the Pioneer of Cannabis Chemistry in Israel, Professor Raphi Mechoulam, Sir Marc Feldmann's Laboratory in Oxford, and 180 Life Sciences Scientists, Identifies a Non-Psychoactive Cannabidiol (CBD) Analogue Expected to Move Forward in Clinical Development for Inflammation and Pain Collaboration Between the Pioneer of Cannabis Chemistry in Israel, Professor Raphi Mechoulam, Sir Marc Feldmann's Laboratory in Oxford, and 180 Life Sciences Scientists, Identifies a Non-Psychoactive Cannabidiol (CBD) Analogue Expected to Move Forward in Clinical Development for Inflammation and Pain

180 Life Sciences Announces Selection of Lead Synthetic CBD Analogue

180 Life Sciences Corp (NASDAQ: ATNF) shares are trading higher Monday after the company announced it regained compliance with the Nasdaq. The company was notified Jan. 6 it did not meet the listing requirements for the Nasdaq.

180 Life Science Corp Nears Key Levels And Could Breakout Soon

MENLO PARK, Calif., July 12, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, announced today that it has regained Nasdaq Compliance for Listing Rules 5605(b)(1) and 5605(c)(2).

180 Life Sciences Regains Nasdaq Compliance for Listing Rules 5605(b)(1) and 5605(c)(2)

MENLO PARK, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, announced today that it has joined the Russell Microcap® Index, effective after the U.S. market opens today, June 28.

News for 180 Life Sciences Stock (ATNF)